Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen

Pediatric Blood and Cancer

Volumn 56, Issue 7, 2011, Pages 1032-1040

  Mastrangelo, Stefano ^a   Rufini, Vittoria ^a   Ruggiero, Antonio ^a   Di Giannatale, Angela ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Chemotherapy; Combined therapy; Induction regimen; MIBG; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; ISOTRETINOIN; MELPHALAN; POTASSIUM IODIDE; THYROXINE; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MUCOSA INFLAMMATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; INFANT; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; PILOT PROJECTS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 79954492593     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22986     Document Type: Article

References (36)

1. Cohn SL, Pearson ADJ, London WB, et al. The international neuroblastoma risk group (INRG) classification system: An INRG task force report. J Clin Oncol 2009; 27: 289-297.
2. Kaneko M, Tsuchida Y, Uchino J, et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 190-197.
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
4. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005; 23: 532-540.
5. Pearson AD, Craft AW, Pinkerton CR, et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992; 28A: 1654-1659.
6. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923-931.
7. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009; 46: 52-63.
8. Shukla NN, Trippett TM. Non-Hodgkin's lymphoma in children and adolescents. Curr Oncol Rep 2006; 8: 387-394.
9. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486-2491.
10. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22: 3909-3915.
11. Pearson AD, Pinkerton CR, Lewis IJ, et al., European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 2008; 9: 247-256.
12. Meller S. Targeted radiotherapy for neuroblastoma. Arch Dis Child 1997; 77: 389-391.
13. 125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1985; 45: 6366-6370.
14. Iavarone A, Lasorella A, Servidei T, et al. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993; 53: 304-309.
15. 131I-metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 1998; 31: 22-26.
16. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004; 22: 2452-2460.
17. 131I]metaiodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995; 31A: 606-611.
18. Mastrangelo R, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 1997; 31: 153-158.
19. Mastrangelo S, Tornesello A, Bembo V, et al. Radioresistant sensitization of neuroblastoma by cisplatin? Med Pediatr Oncol 2000; 35: 77-79.
20. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460-464.
21. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
22. 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31: 256-261.
23. Millar JL, Hudspith BN. Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with gamma-irradiation. Cancer Treat Rep 1976; 60: 409-414.
24. Gazzetta Ufficiale della Repubblica Italiana. Attuazione delle direttive Euratom 80/836, 84/467, 84/466, 89/618, 90/641 e 92/3 in materia di radiazioni ionizzanti, ai sensi del decreto legislativo 17/3/ 1995, n. 230. Supplemento Ordinario alla Gazzetta Ufficiale della Repubblica Italiana 1995;136:140.
25. Hutchinson RJ, Sisson JC, Shapiro B, et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 1992; 15: 226-232.
26. De Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008; 44: 551-556.
27. 131I-MIBG. J Nucl Med 2001; 42: 1713-1721.
28. 131I-meta-iodobenzylguanidine. Eur J Nucl Med 1988; 14: 337-340.
29. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992; 10: 1889-1896.
30. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005; 44: 232-239.
31. Dwamena BA, Zempel S, Klopper JF, et al. Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma. Clin Nucl Med 1998; 23: 441-445.
32. Simone JV. The treatment of neuroblastoma. J Clin Oncol 1984; 2: 717-718.
33. 131I-metaiodobenzylguanidine in the treatment of neuroblastoma at diagnosis. Am J Pediatr Hematol Oncol 1989; 11: 28-31.
34. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236.
35. Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27: 1020-1025.
36. 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999; 35: 1227-1234.